Discover open access scientific publications

Search, annotate, share and cite publications

Publications by M. Martak

P3.13-11 Advanced NSCLC Treated With Gefitinib or Erlotinib for Five Years or Longer - Retrospective Slovakian Study

Journal of Thoracic Oncology

English

Related publications

The Effect of Combined Treatment With Sodium Phenylbutyrate and Cisplatin, Erlotinib, or Gefitinib on Resistant NSCLC Cells

Clinical Pharmacology: Advances and Applications

Pharmacology

2018

English

Role of KRAS-LCS6 Polymorphism in Advanced NSCLC Patients Treated With Erlotinib or Docetaxel in Second Line Treatment (TAILOR)

Scientific Reports

Multidisciplinary

2015

English

Evaluation of Patient Education System to Improve Their Understanding in Patients Treated With Erlotinib or Gefitinib

Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)

2015

English

P3.13-17 a Retrospective Study: Central Nervous System Response to Osimertinib in Patients With Advanced NSCLC

Journal of Thoracic Oncology

English

Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients With Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus

Clinical Cancer Research

Cancer Research

Oncology

2007

English

Phase II Trials of Erlotinib or Gefitinib in Patients With Recurrent Meningioma

Journal of Neuro-Oncology

English

Phase II Study of Erlotinib Plus Tivantinib (ARQ 197) in Patients With Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small-Cell Lung Cancer Just After Progression on EGFR-TKI, Gefitinib or Erlotinib

English

Successful Rechallenge With Gefitinib for an Initial Erlotinib-Responder With Advanced Lung Adenocarcinoma

Tuberculosis and Respiratory Diseases

English

Brief Report: Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced Non–Small-Cell Lung Cancer With Sensitizing EGFR Mutation

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by M. Martak

P3.13-11 Advanced NSCLC Treated With Gefitinib or Erlotinib for Five Years or Longer - Retrospective Slovakian Study

Related publications

The Effect of Combined Treatment With Sodium Phenylbutyrate and Cisplatin, Erlotinib, or Gefitinib on Resistant NSCLC Cells

Role of KRAS-LCS6 Polymorphism in Advanced NSCLC Patients Treated With Erlotinib or Docetaxel in Second Line Treatment (TAILOR)

Evaluation of Patient Education System to Improve Their Understanding in Patients Treated With Erlotinib or Gefitinib

P3.13-17 a Retrospective Study: Central Nervous System Response to Osimertinib in Patients With Advanced NSCLC

Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients With Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus

Phase II Trials of Erlotinib or Gefitinib in Patients With Recurrent Meningioma

Phase II Study of Erlotinib Plus Tivantinib (ARQ 197) in Patients With Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small-Cell Lung Cancer Just After Progression on EGFR-TKI, Gefitinib or Erlotinib

Successful Rechallenge With Gefitinib for an Initial Erlotinib-Responder With Advanced Lung Adenocarcinoma

Brief Report: Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced Non–Small-Cell Lung Cancer With Sensitizing EGFR Mutation